HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI

References

• Sequist LV , WaltmanBA , Dias-SantagataDet al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med.3(75), 75ra26 (2011).
   PubMed Web of Science ®Google Scholar
• Yu HA , ArcilaME , RekhtmanNet al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res.19(8), 2240–2247 (2013).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL , ThongprasertSet al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , MoritaS , YatabeYet al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase III trial. Lancet Oncol.11(2), 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Maemondo M , InoueA , KobayashiKet al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med.362(25), 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Janne PA , WangX , SocinskiMAet al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J. Clin. Oncol.30(17), 2063–2069 (2012).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS , VansteenkisteJ , PlanchardDet al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N. Engl. J. Med.382(1), 41–50 (2020).
   PubMed Web of Science ®Google Scholar
• Soria JC , OheY , VansteenkisteJet al. Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer. N. Engl. J. Med.378(2), 113–125 (2018).
   PubMed Web of Science ®Google Scholar
• Janne PA , PlanchardD , ChengYet al. Osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2). Presented at: 2023 IASLC World Conference on Lung Cancer.Republic of Singapore, Singapore (9–12 September, 2023). Abstract PL03.13.
   Google Scholar
• Lu S , DongX , JianHet al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J. Clin. Oncol.40(27), 3162–3171 (2022).
   PubMed Web of Science ®Google Scholar
• Soria JC , WuYL , NakagawaKet al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a Phase III randomised trial. Lancet Oncol.16(8), 990–998 (2015).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL , AhnMJet al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N. Engl. J. Med.376(7), 629–640 (2017).
   PubMed Web of Science ®Google Scholar
• Han B , YangL , WangX , YaoL. Efficacy of pemetrexed-based regimens in advanced non-small-cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. Onco. Targets Ther.11, 2121–2129 (2018).
   PubMed Web of Science ®Google Scholar
• Mok TSK , NakagawaK , ParkKet al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small-cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Ann. Oncol.33(Suppl. 9), S1561–S1562 (2002).
   Google Scholar
• Yang CH , LeeDH , LeeJSet al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase III KEYNOTE-789 study. J. Clin. Onco.41(Suppl. 17), abstract LBA9000 (2023).
   Web of Science ®Google Scholar
• Lu S , WuL , JianHet al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, Phase III trial. Lancet Respir. Med.11(7), 624–636 (2023).
   PubMed Web of Science ®Google Scholar
• Zhou C , DongX , ChenGet al. IMpower151: phase III study of atezolizumab+bevacizumab+chemotherapy in first-line metastatic nonsquamous NSCLC. Presented at: 2023 IASLC World Conference on Lung Cancer.Republic of Singapore, Singapore (9–12 September 2023). Abstract OA09.06.
   Google Scholar
• Leonetti A , SharmaS , MinariR , PeregoP , GiovannettiE , TiseoM. Resistance mechanisms to osimertinib in EGFR-mutated non-small-cell lung cancer. Br. J. Cancer121(9), 725–737 (2019).
   PubMed Web of Science ®Google Scholar
• Sequist LV , HanJY , AhnMJet al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, Phase Ib study. Lancet Oncol.21(3), 373–386 (2020).
   PubMed Web of Science ®Google Scholar
• Wang S , SongY , LiuD. EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett.385, 51–54 (2017).
   PubMed Web of Science ®Google Scholar
• Wu YL , ZhangL , KimDWet al. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J. Clin. Oncol.36(31), 3101–3109 (2018).
   PubMed Web of Science ®Google Scholar
• Mu Y , HaoX , XingPet al. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. J. Cancer Res. Clin. Oncol.146(9), 2427–2433 (2020).
   PubMed Web of Science ®Google Scholar
• Cooper AJ , SequistLV , LinJJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat. Rev. Clin. Oncol.19(8), 499–514 (2022).
   PubMed Web of Science ®Google Scholar
• Johnson M , GarassinoMC , MokT , MitsudomiT. Treatment strategies and outcomes for patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies. Lung Cancer170, 41–51 (2022).
   PubMed Web of Science ®Google Scholar
• Scharpenseel H , HanssenA , LogesSet al. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small-cell lung cancer patients. Sci. Rep.9(1), 7406 (2019).
   PubMedGoogle Scholar
• Yi ES , HarclerodeD , GondoMet al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small-cell lung carcinomas. Mod. Pathol.10(2), 142–148 (1997).
   PubMed Web of Science ®Google Scholar
• Li Q , ZhangR , YanHet al. Prognostic significance of HER3 in patients with malignant solid tumors. Oncotarget8(40), 67140–67151 (2017).
   PubMedGoogle Scholar
• Yonesaka K , TanizakiJ , MaenishiOet al. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated non-small-cell Lung Cancer. Clin. Cancer Res.28(2), 390–403 (2022).
   PubMed Web of Science ®Google Scholar
• Engelman JA , ZejnullahuK , MitsudomiTet al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science316(5827), 1039–1043 (2007).
   PubMed Web of Science ®Google Scholar
• Hashimoto Y , KoyamaK , KamaiYet al. A Novel HER3-Targeting antibody–drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. Clin. Cancer Res.25(23), 7151–7161 (2019).
   PubMed Web of Science ®Google Scholar
• Koganemaru S , KubokiY , KogaYet al. U3-1402, a Novel HER3-Targeting antibody–drug Conjugate, for the Treatment of Colorectal Cancer. Mol. Cancer Ther.18(11), 2043–2050 (2019).
   PubMed Web of Science ®Google Scholar
• Nakada T , SugiharaK , JikohT , AbeY , AgatsumaT. The Latest Research and Development into the antibody–drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem. Pharm. Bull. (Tokyo)67(3), 173–185 (2019).
   PubMed Web of Science ®Google Scholar
• Ogitani Y , AidaT , HagiharaKet al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin. Cancer Res.22(20), 5097–5108 (2016).
   PubMed Web of Science ®Google Scholar
• Yonesaka K , TakegawaN , WatanabeSet al. An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. Oncogene38(9), 1398–1409 (2019).
   PubMed Web of Science ®Google Scholar
• Koyama K , HashimotoY , KamaiYet al. U3-1402, a novel HER3-targeting antibody–drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient internalization. Presented at: American Academy of Cancer Research. (2019).
   Google Scholar
• Jänne PA , BaikC , SuWCet al. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated non-small-cell Lung Cancer. Cancer Discov.12(1), 74–89 (2022).
   PubMed Web of Science ®Google Scholar
• Yu HA , GotoY , HayashiHet al. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J. Clin. Oncol.JCO2301476 (2023).
   Web of Science ®Google Scholar
• Yu HA , YangJC , HayashiHet al. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC. Future Oncol.19(19), 1319–1329 (2023).
   PubMed Web of Science ®Google Scholar